A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Phase 2 Completed 20 enrolled Alios Biopharma Inc. Vertex Pharmaceuticals Incorporated · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.

Timeline

Start: 2013-02-28
Primary completion: 2014-06-30
Completion: 2014-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-135	Small molecule	—	Oral
Background	Ribavirin	Small molecule	—	—

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Summary

Timeline

Drugs

Indications